APLI:TSX-Appili Therapeutics Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 0.09

Change

0.00 (0.00)%

Market Cap

CAD 6.06M

Volume

0.14M

Avg Analyst Target

N/A

Avg User Target

CAD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Appili Therapeutics Inc (APLI) Stock Analysis:
Based on the Appili Therapeutics Inc stock forecasts from 0 analysts, the average analyst target price for Appili Therapeutics Inc is not available over the next 12 months. Appili Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Appili Therapeutics Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Appili Therapeutics Inc’s stock price was CAD 0.09. Appili Therapeutics Inc’s stock price has changed by -10.53% over the past week, -26.09% over the past month and -89.88% over the last year.

No recent analyst target price found for Appili Therapeutics Inc
No recent average analyst rating found for Appili Therapeutics Inc

About

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TRIL:CA Trillium Therapeutics Inc

N/A

CAD2.43B 1.80 N/A
BLU:CA BELLUS Health Inc

N/A

CAD1.16B N/A N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
FRX:CA Fennec Pharmaceuticals Inc

N/A

CAD0.19B 30.20 N/A
APS:CA Aptose Biosciences Inc

N/A

CAD0.13B N/A N/A
IMV:CA IMV Inc

N/A

CAD0.11B -99,999.99 N/A
BCT:CA BriaCell Therapeutics Corp.

N/A

CAD0.10B N/A N/A
ONC:CA Oncolytics Biotech Inc

N/A

CAD0.08B N/A N/A
RVX:CA Resverlogix Corp

N/A

CAD0.07B 27.50 26.37
MDNA:CA Medicenna Therapeutics Corp

N/A

CAD0.07B 5.40 N/A

ETFs Containing APLI:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.09% 56% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.09% 56% F 14% F
Trailing 12 Months  
Capital Gain -89.88% 6% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.88% 6% F N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.17% 41% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.17% 41% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 62.54% 59% F 13% F
Risk Adjusted Return 0.28% 41% F 20% F
Market Capitalization 6.06M 12% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.40 93% A 54% F
Price / Cash Flow Ratio -0.53 12% F 76% C
EV/EBITDA 0.01 100% A+ 100% A+
Management Effectiveness  
Return on Equity -316.15% 33% F 3% F
Return on Invested Capital -121.61% 29% F 3% F
Return on Assets -105.55% 18% F 1% F
Debt to Equity Ratio 7.43% 78% C+ 85% B
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.84 82% B- 49% F
Short Percent 0.56% 25% F 69% D+
Beta 1.10 56% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.